Lonza Group Ltd (LONN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonzas client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The companys key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Venture Financing 19
Odyssey Thera Raises US$3 Million In Venture Financing 19
Private Equity 20
Kainos Capital Acquires InterHealth Nutraceuticals 20
Partnerships 21
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 21
Synpromics Enters into Partnership with Lonza 22
Lonza Enters into Agreement with Denali Therapeutics 23
Capsugel Enters into Agreement with Pulmatrix 24
Lonza Enters into Agreement with Kodiak Sciences 25
CiMaas Enters into Agreement with PharmaCell 26
Lonza Partners with Octane Biotech 27
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 28
Lonza and AMYRA Biotech Enter into Agreement 29
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 30
Catalent Pharma Solutions Enters Into Agreement With Bend Research 31
CSIRO Enters Into Co-Development Agreement With Lonza 32
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 33
Licensing Agreements 34
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
CytoDyn Enters into Licensing Agreement with Lonza Sales 35
Xbiotech Enters Into Licensing Agreement With Lonza Sales 36
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 37
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 39
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 40
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 41
Pierre Fabre Enters into Licensing Agreement with Lonza 42
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 45
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 46
Lonza Enters into Licensing Agreement with arGEN-X 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 50
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 51
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 52
Equity Offering 53
Lonza Raise USD2.24 Billion in Rights Offering of Shares 53
Lonza Raises USD871 Million in Private Placement of Shares 54
Debt Offering 55
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 55
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 56
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 57
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 58
Asset Transactions 59
PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 59
Acquisition 60
Lonza Group Acquires micromacinazione from Cross 60
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 61
Lonza Group Acquires PharmaCell 63
Lonza Acquires HansaBioMed Life Sciences 64
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 65
Lonza Acquires Triangle Research Labs from PBM Capital 66
Lonza May Acquire Catalent 67
Capsugel Acquires Xcelience 68
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 69
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 70
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 71
Capsugel Belgium Acquires Encap Drug Delivery 72
Lonza Group Ltd - Key Competitors 73
Lonza Group Ltd - Key Employees 74
Lonza Group Ltd - Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Joint Venture 78
Recent Developments 79
Strategy And Business Planning 79
May 02, 2018: Lonza Consumer Health and Nutrition Invests in Greenwood, SC (USA) Facility to Expand Specialty Ingredients Production 79
Feb 27, 2018: Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil 80
Feb 14, 2018: Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth 81
Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 82
Financial Announcements 83
May 04, 2018: Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers 83
Jan 31, 2018: Lonza Reports Record-Breaking Full-Year Results with Double-Digit Lonza Standalone Sales Growth and More than 26% CORE EBIT Growth in a Major Transformational Year 85
Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 89
Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 91
Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 93
Corporate Communications 95
Jun 27, 2017: Lonzas CHRO Elected to Board of Advance Women in Swiss Business 95
Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 96
Product News 97
Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 97
Jun 19, 2018: Lonza s Capsule Delivery Solutions Launches Capsugel Vcaps Gen C a New Specialty Polymer Capsule 98
May 22, 2018: Lonza Further Strengthens Hepatocytes Portfolio with Addition of Hepatic Non-Parenchymal Cells 99
Feb 15, 2018: Study Further Positions Lonzas UC-II A Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market 100
Other Significant Developments 101
Jul 02, 2018: Lonza Launches New Bioscience Website 101
May 04, 2018: Lonza to Invest in Portsmouth, NH (USA) Site, Including Mid-Scale Biologics 102
Mar 26, 2018: Lonza to Host New Webinar: Integrating Devices into Quality Systems 103
Feb 20, 2018: Lonza Expands Encapsulation and HPAPI Capabilities in North America 104
Dec 14, 2017: Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules 105
Appendix 107
Methodology 107
About GlobalData 107
Contact Us 107
Disclaimer 107

List Of Tables

List of Tables
Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Odyssey Thera Raises US$3 Million In Venture Financing 19
Kainos Capital Acquires InterHealth Nutraceuticals 20
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 21
Synpromics Enters into Partnership with Lonza 22
Lonza Enters into Agreement with Denali Therapeutics 23
Capsugel Enters into Agreement with Pulmatrix 24
Lonza Enters into Agreement with Kodiak Sciences 25
CiMaas Enters into Agreement with PharmaCell 26
Lonza Partners with Octane Biotech 27
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 28
Lonza and AMYRA Biotech Enter into Agreement 29
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 30
Catalent Pharma Solutions Enters Into Agreement With Bend Research 31
CSIRO Enters Into Co-Development Agreement With Lonza 32
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 33
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
CytoDyn Enters into Licensing Agreement with Lonza Sales 35
Xbiotech Enters Into Licensing Agreement With Lonza Sales 36
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 37
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 39
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 40
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 41
Pierre Fabre Enters into Licensing Agreement with Lonza 42
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 45
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 46
Lonza Enters into Licensing Agreement with arGEN-X 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 50
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 51
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 52
Lonza Raise USD2.24 Billion in Rights Offering of Shares 53
Lonza Raises USD871 Million in Private Placement of Shares 54
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 55
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 56
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 57
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 58
PolyPeptide Acquires Peptides Business and Operations in Braine, Belgium from Lonza 59
Lonza Group Acquires micromacinazione from Cross 60
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 61
Lonza Group Acquires PharmaCell 63
Lonza Acquires HansaBioMed Life Sciences 64
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 65
Lonza Acquires Triangle Research Labs from PBM Capital 66
Lonza May Acquire Catalent 67
Capsugel Acquires Xcelience 68
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 69
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 70
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 71
Capsugel Belgium Acquires Encap Drug Delivery 72
Lonza Group Ltd, Key Competitors 73
Lonza Group Ltd, Key Employees 74
Lonza Group Ltd, Subsidiaries 75
Lonza Group Ltd, Joint Venture 78

List Of Figures

List of Figures
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd (LONN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem

USD 250 View Report

Lonza Group Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Lonza Group Ltd Company Profile is a detailed strategic and analytical report on Lonza Group Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

The American Energy Group Ltd - Oil & Gas - Deals and Alliances Profile

The American Energy Group Ltd (American Energy Group), formerly Belize-American Corp, is an oil and natural gas company that develops, explores, acquire, and produces oil and natural gas producing assets.

USD 250 View Report

Pinnacle Investment Management Group Ltd (PNI) - Financial and Strategic SWOT Analysis Review

Pinnacle Investment Management Group Ltd (PNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available